Oncology CRA
Track the protocol-required specimen, collection dates, and reports and reconcile the source with data entry.
Oncology trial operations
Myeloma studies can bring prior treatment records, response assessments, and transplant or laboratory schedules into one review. Give each dependency a clear owner before opening a cohort or setting a data milestone.
Multiple myeloma is a cancer of plasma cells. In relapsed or refractory cohorts, prior regimens, drug-class exposure, and response history can be spread across institutions. For a response or measurable residual disease (MRD) endpoint, a completed visit can still leave an incomplete assessment if a required specimen, central result, or companion lab value is missing.
Start with the protocol and lab manual. Reconcile the assessment date, specimen or accession identifier, lab status, and EDC record before closing the action. Have the Senior CRA follow site evidence and have the study manager coordinate the lab and data teams on unresolved items. The sponsor sets the endpoint and escalation rules.
When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.
Request an executive briefing →Track the protocol-required specimen, collection dates, and reports and reconcile the source with data entry.
Agree who follows lab status and who escalates incomplete results before an endpoint or maintenance review.
Group recurring prior-line discrepancies, missed transplant handoffs, and late marrow or lab results by site and cause.
A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.